Gland Pharma will hold a meeting of the Board of Directors of the Company on 6 August 2024.Powered by Capital Market - Live News

Gland Pharma announced that Srinivas Sadu, the incumbent Managing Director (MD) and CEO, has been appointed as Executive Chairman and CEO of the company, effective 10 June  2024. Srinivas Sadu, a seasoned professional with over two decades of rich experience, has been a key part of Gland`s journey. He assumed the role of MD and CEO on April 25, 2019, and has been instrumental in the company`s growth and success. His career with the company began in 2000, and he steadily rose through the ranks to become chief operating officer in 2011Powered by Capital Market - Live News

Gland Pharma announced that the 46th Annual General Meeting(AGM) of the company will be held on 30 August 2024.Powered by Capital Market - Live News

Gland Pharma announced that the Board of Directors of the Company at its meeting held on 22 May 2024, inter alia, have recommended the final dividend of Rs 20 per equity Share (i.e. 2000%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Gland Pharma rose 144.56% to Rs 192.42 crore in the quarter ended March 2024 as against Rs 78.68 crore during the previous quarter ended March 2023. Sales rose 95.85% to Rs 1537.45 crore in the quarter ended March 2024 as against Rs 785.01 crore during the previous quarter ended March 2023.For the full year,net profit declined 1.10% to Rs 772.46 crore in the year ended March 2024 as against Rs 781.04 crore during the previous year ended March 2023. Sales rose 56.29% to Rs 5664.72 crore in the year ended March 2024 as against Rs 3624.60 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales1537.45785.01 96 5664.723624.60 56 OPM %23.3321.45 -23.5328.27 - PBDT390.84205.15 91 1477.111257.78 17 PBT298.23167.61 78 1132.541111.04 2 NP192.4278.68 145 772.46781.04 -1 Powered by Capital Market - Live News